Edwin Stone, CEO of Cellular Origins, a TTP Company, describes the importance of a smooth clinical to commercial translation and how implementing innovative tools and technologies can support this.
Edwin discusses the need for robust planning in order to accommodate the changing environment we’re working in, prioritizing collaboration and a commitment to finding technological solutions to ensure success.
Edwin also goes on to share how TTP identify gaps in the market to support the industry, with Cellular Origins tackling the manufacturing bottleneck to bring more therapies to patients.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.